Dumont et al. recently demonstrated the potential of combination of HLA-G and PD-1/PD-L1 blockade to confer a greater benefit to cancer patients, particularly for those with nonresponsiveness to anti-PD-1/PD-L1 (98). The gene discussed is CD274; the disease is cancer.